Covered recipient · General Payments record
SIBYL E WRAY
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$137,842.56
216 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $87,139.39 | 31 |
| Consulting Fee | $31,381.49 | 7 |
| Travel and Lodging | $14,885.14 | 32 |
| Food and Beverage | $4,327.54 | 144 |
| Education | $109.00 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biogen, Inc. | $46,760.86 | 49 |
| GENZYME CORPORATION | $43,594.37 | 47 |
| EMD Serono, Inc. | $23,069.99 | 26 |
| Genentech USA, Inc. | $16,154.06 | 22 |
| F. Hoffmann-La Roche AG | $5,377.89 | 6 |
| Celgene Corporation | $1,884.31 | 2 |
| Novartis Pharmaceuticals Corporation | $379.33 | 25 |
| Avanir Pharmaceuticals, Inc. | $216.25 | 11 |
| Supernus Pharmaceuticals, Inc. | $148.35 | 13 |
| Teva Pharmaceuticals USA, Inc. | $79.99 | 5 |
| Alexion Pharmaceuticals, Inc. | $75.56 | 3 |
| ASSERTIO THERAPEUTICS, Inc. | $40.57 | 3 |
| ACADIA Pharmaceuticals Inc | $28.18 | 2 |
| Amgen Inc. | $19.12 | 1 |
| JAZZ PHARMACEUTICALS INC. | $13.73 | 1 |
Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SIBYL E WRAY
NPI 1881662591 · CMS profile ID 357387
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
KNOXVILLE, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1881662591?year=2019&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SIBYL E WRAY, NPI 1881662591, CMS profile ID 357387. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881662591?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). SIBYL E WRAY, NPI 1881662591, CMS profile ID 357387. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881662591?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- SIBYL E WRAY, NPI 1881662591, CMS profile ID 357387, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881662591?year=2019&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
216 matching records · $137,842.56 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–216 of 216.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $247.81 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694237067 | CMS |
| GENZYME CORPORATION | $129.38 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694237069 | CMS |
| GENZYME CORPORATION | $46.13 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694237071 | CMS |
| GENZYME CORPORATION | $52.44 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694237073 | CMS |
| GENZYME CORPORATION | $64.59 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694237075 | CMS |
| GENZYME CORPORATION | $3,797.50 | 02/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694237077 | CMS |
| GENZYME CORPORATION | $674.98 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694318725 | CMS |
| Biogen, Inc. | $13.48 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660661953 | CMS |
| Avanir Pharmaceuticals, Inc. | $19.78 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 653612585 | CMS |
| Biogen, Inc. | $3,150.00 | 02/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660661955 | CMS |
| Novartis Pharmaceuticals Corporation | $11.45 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660180407 | CMS |
| Supernus Pharmaceuticals, Inc. | $9.03 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702370299 | CMS |
| Biogen, Inc. | $11.89 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660661951 | CMS |
| Avanir Pharmaceuticals, Inc. | $19.78 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 653612593 | CMS |
| Novartis Pharmaceuticals Corporation | $15.29 | 01/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660180405 | CMS |
| Biogen, Inc. | $10.64 | 01/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660661937 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $102,594.64 | 24 |
| PY2025 | Principal investigator | $4,308,530.70 | 399 |
| PY2024 | Recipient | $683,083.05 | 117 |
| PY2024 | Principal investigator | $3,539,953.58 | 333 |
| PY2023 | Recipient | $604,756.50 | 136 |
| PY2023 | Principal investigator | $4,147,950.42 | 203 |
| PY2022 | Recipient | $182,446.41 | 68 |
| PY2022 | Principal investigator | $4,281,973.08 | 159 |
| PY2021 | Recipient | $307,167.78 | 80 |
| PY2021 | Principal investigator | $2,352,572.30 | 85 |
| PY2020 | Recipient | $121,997.32 | 42 |
| PY2020 | Principal investigator | $1,469,195.04 | 43 |
| PY2019 | Recipient | $91,632.25 | 46 |
| PY2019 | Principal investigator | $1,085,250.60 | 84 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
423 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $455.00 | 12/22/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152339 |
| Principal investigator 1 | GENZYME CORPORATION | $96.00 | 12/22/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152345 |
| Principal investigator 1 | Genentech, Inc. | $10,964.00 | 12/22/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) | No dispute reported | 06/30/2026 | 1211655020 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,473.00 | 12/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654882 |
| Principal investigator 1 | Genentech, Inc. | $3,374.00 | 12/19/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655409 |
| Principal investigator 1 | Genentech, Inc. | $1,954.00 | 12/17/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211655023 |
| Principal investigator 1 | Genentech, Inc. | $27,033.00 | 12/16/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) | No dispute reported | 06/30/2026 | 1211655015 |
| Principal investigator 1 | Genentech, Inc. | $8,918.00 | 12/16/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655399 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654864 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654869 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654873 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654877 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $118.02 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654885 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654890 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654893 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $78.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654896 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654899 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $118.02 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654903 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654906 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654910 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $156.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654918 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654925 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654928 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654932 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 12/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654936 |
| Principal investigator 1 | Genentech, Inc. | $1,719.00 | 12/12/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211655011 |
| Principal investigator 1 | TG Therapeutics, Inc. | $167.00 | 12/11/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198071 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $950.00 | 12/10/2025 | Non-covered Recipient Entity Sibyl Wray Md Neourology Pc | A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. | No dispute reported | 06/30/2026 | 1235993695 |
| Principal investigator 1 | Genentech, Inc. | $228.00 | 12/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655269 |
| Principal investigator 1 | Genentech, Inc. | $9,035.00 | 12/05/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655394 |
| Principal investigator 1 | Genentech, Inc. | $8,848.00 | 12/04/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655275 |
| Principal investigator 1 | Genentech, Inc. | $133.00 | 12/01/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655403 |
| Principal investigator 1 | TG Therapeutics, Inc. | $21,688.15 | 12/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198091 |
| Principal investigator 1 | TG Therapeutics, Inc. | $18,614.50 | 11/30/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198085 |
| Principal investigator 1 | Genentech, Inc. | $1,285.00 | 11/25/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211655004 |
| Principal investigator 1 | GENZYME CORPORATION | $3,069.00 | 11/24/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152334 |
| Principal investigator 1 | Genentech, Inc. | $15,995.00 | 11/20/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO) | No dispute reported | 06/30/2026 | 1211655008 |
| Principal investigator 1 | Genentech, Inc. | $1,390.00 | 11/20/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655261 |
| Principal investigator 1 | Genentech, Inc. | $5,032.00 | 11/20/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655386 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,680.00 | 11/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654914 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 11/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654922 |
| Principal investigator 1 | GENZYME CORPORATION | $8,366.60 | 11/17/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152308 |
| Principal investigator 1 | GENZYME CORPORATION | $11,842.30 | 11/17/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152314 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 11/17/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655388 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,401.74 | 11/12/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198061 |
| Principal investigator 1 | Genentech, Inc. | $92.00 | 11/10/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655265 |
| Recipient | Novartis Pharmaceuticals Corporation | $509.29 | 11/07/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291573 |
| Principal investigator 1 | Genentech, Inc. | $210.00 | 11/05/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654994 |
| Principal investigator 1 | TG Therapeutics, Inc. | $9,189.45 | 11/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198063 |
| Principal investigator 1 | TG Therapeutics, Inc. | $10,182.00 | 11/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198069 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,099.30 | 11/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198083 |
| Principal investigator 1 | TG Therapeutics, Inc. | $75.00 | 10/30/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198067 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,303.50 | 10/30/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198089 |
| Principal investigator 1 | Genentech, Inc. | $5,725.00 | 10/28/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211655001 |
| Principal investigator 1 | Genentech, Inc. | $2,261.00 | 10/28/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655243 |
| Principal investigator 1 | Genentech, Inc. | $2,006.00 | 10/28/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655254 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 10/27/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655257 |
| Principal investigator 1 | Genentech, Inc. | $223.00 | 10/23/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655370 |
| Principal investigator 1 | Genentech, Inc. | $9,561.00 | 10/23/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655380 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 10/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654793 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,680.00 | 10/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654834 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 10/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654847 |
| Principal investigator 1 | GENZYME CORPORATION | $2,700.00 | 10/20/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152191 |
| Principal investigator 1 | GENZYME CORPORATION | $175.48 | 10/20/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152198 |
| Principal investigator 1 | GENZYME CORPORATION | $1,392.01 | 10/20/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152228 |
| Principal investigator 1 | GENZYME CORPORATION | $336.70 | 10/20/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152233 |
| Principal investigator 1 | GENZYME CORPORATION | $1,085.00 | 10/20/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152251 |
| Principal investigator 1 | Genentech, Inc. | $126.00 | 10/20/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655383 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 10/17/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655373 |
| Principal investigator 1 | Genentech, Inc. | $2,516.00 | 10/15/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655376 |
| Principal investigator 1 | GENZYME CORPORATION | $1,107.00 | 10/14/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152205 |
| Principal investigator 1 | GENZYME CORPORATION | $682.89 | 10/14/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152211 |
| Principal investigator 1 | GENZYME CORPORATION | $656.80 | 10/14/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152215 |
| Principal investigator 1 | GENZYME CORPORATION | $136.80 | 10/14/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152219 |
| Principal investigator 1 | GENZYME CORPORATION | $115.00 | 10/14/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152224 |
| Principal investigator 1 | GENZYME CORPORATION | $1,755.00 | 10/14/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152238 |
| Principal investigator 1 | GENZYME CORPORATION | $166.24 | 10/14/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152243 |
| Principal investigator 1 | Genentech, Inc. | $1,240.00 | 10/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654998 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 10/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655250 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,298.88 | 10/08/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198065 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,137.24 | 10/08/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198087 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $878.52 | 10/07/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190300089 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $84.84 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654797 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654801 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654806 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654812 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $156.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654815 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654819 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654824 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $84.84 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654826 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654830 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654837 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654842 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654850 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654854 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $32.40 | 10/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654859 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,644.65 | 09/30/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198003 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,236.00 | 09/30/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198041 |
| Principal investigator 1 | GENZYME CORPORATION | $5,682.90 | 09/29/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152171 |
| Principal investigator 1 | Genentech, Inc. | $2,282.00 | 09/29/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654981 |
| Principal investigator 1 | Celgene Corporation | $25,937.00 | 09/26/2025 | Non-covered Recipient Entity Hope Neurology, PLLC | A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. | No dispute reported | 06/30/2026 | 1222306233 |
| Principal investigator 1 | Genentech, Inc. | $136.00 | 09/25/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655362 |
| Principal investigator 1 | Genentech, Inc. | $185.00 | 09/25/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655366 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,604.06 | 09/25/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198059 |
| Principal investigator 1 | Genentech, Inc. | $56.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655217 |
| Principal investigator 1 | Genentech, Inc. | $161.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655227 |
| Recipient | Novartis Pharma AG | $76.67 | 09/24/2025 | Covered Recipient Physician | CLOU064C12301, CLOU064C12302 | No dispute reported | 06/30/2026 | 1248109023 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655104 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655107 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655111 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655115 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655119 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655123 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655127 |
| Principal investigator 1 | Roche Products Limited | $33.80 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655138 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655142 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 09/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655146 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 09/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654700 |
| Principal investigator 1 | Genentech, Inc. | $9,007.00 | 09/22/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655234 |
| Principal investigator 1 | Genentech, Inc. | $8,116.00 | 09/18/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655344 |
| Principal investigator 1 | TG Therapeutics, Inc. | $285.00 | 09/16/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198053 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654718 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654720 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654724 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654729 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654734 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $31.92 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654742 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654758 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654771 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654785 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $39.00 | 09/15/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654790 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,548.50 | 09/10/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198051 |
| Principal investigator 1 | GENZYME CORPORATION | $670.00 | 09/08/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152158 |
| Recipient | TG Therapeutics, Inc. | $807.35 | 09/08/2025 | Covered Recipient Physician | RMS302 | No dispute reported | 06/30/2026 | 1226200850 |
| Principal investigator 1 | Genentech, Inc. | $2,800.00 | 09/03/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655348 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,781.00 | 08/31/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198001 |
| Principal investigator 1 | TG Therapeutics, Inc. | $9,335.30 | 08/31/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198039 |
| Principal investigator 1 | Genentech, Inc. | $1,113.00 | 08/27/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654977 |
| Principal investigator 1 | GENZYME CORPORATION | $32.00 | 08/25/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152128 |
| Principal investigator 1 | GENZYME CORPORATION | $202.00 | 08/25/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152140 |
| Principal investigator 1 | Genentech, Inc. | $56.00 | 08/22/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655221 |
| Principal investigator 1 | Genentech, Inc. | $8,886.00 | 08/20/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655224 |
| Principal investigator 1 | GENZYME CORPORATION | $32.00 | 08/18/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152122 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 08/18/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655358 |
| Principal investigator 1 | Genentech, Inc. | $5,890.00 | 08/15/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655239 |
| Principal investigator 1 | Genentech, Inc. | $2,370.00 | 08/13/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654990 |
| Principal investigator 1 | TG Therapeutics, Inc. | $849.78 | 08/13/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198015 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,924.50 | 08/12/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198049 |
| Principal investigator 1 | GENZYME CORPORATION | $80,214.00 | 08/11/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152113 |
| Principal investigator 1 | Genentech, Inc. | $1,817.00 | 08/11/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655354 |
| Principal investigator 1 | Genentech, Inc. | $850.00 | 08/07/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654987 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,601.16 | 08/07/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198057 |
| Principal investigator 1 | GENZYME CORPORATION | $6,044.30 | 08/04/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152051 |
| Principal investigator 1 | GENZYME CORPORATION | $12,088.60 | 08/04/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152057 |
| Principal investigator 1 | TG Therapeutics, Inc. | $12,664.00 | 08/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198013 |
| Principal investigator 1 | TG Therapeutics, Inc. | $8,629.25 | 07/31/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197999 |
| Principal investigator 1 | TG Therapeutics, Inc. | $12,415.90 | 07/31/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198037 |
| Principal investigator 1 | TG Therapeutics, Inc. | $574.50 | 07/29/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198047 |
| Principal investigator 1 | GENZYME CORPORATION | $500.00 | 07/28/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152101 |
| Principal investigator 1 | GENZYME CORPORATION | $939.00 | 07/28/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152716 |
| Principal investigator 1 | Roche Products Limited | $750.00 | 07/28/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655134 |
| Principal investigator 1 | TG Therapeutics, Inc. | $150.00 | 07/28/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198011 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 07/23/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654703 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 07/23/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654706 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $31.92 | 07/23/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654713 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 07/23/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654731 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 07/23/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654738 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,680.00 | 07/23/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654761 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 07/23/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654781 |
| Principal investigator 1 | Genentech, Inc. | $5,757.00 | 07/21/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655210 |
| Principal investigator 1 | Genentech, Inc. | $2,800.00 | 07/21/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655336 |
| Principal investigator 1 | TG Therapeutics, Inc. | $574.50 | 07/21/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198045 |
| Principal investigator 1 | TG Therapeutics, Inc. | $866.78 | 07/20/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198009 |
| Principal investigator 1 | TG Therapeutics, Inc. | $225.00 | 07/16/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198007 |
| Principal investigator 1 | Genentech, Inc. | $75.00 | 07/10/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654974 |
| Principal investigator 1 | Genentech, Inc. | $1,452.00 | 07/10/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655214 |
| Principal investigator 1 | Genentech, Inc. | $9,363.00 | 07/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655340 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,002.90 | 07/07/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198055 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $438.00 | 07/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654709 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $44.00 | 07/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654745 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $31.92 | 07/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654749 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $24.00 | 07/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654754 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $291.00 | 07/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654767 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 07/02/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654776 |
| Principal investigator 1 | GENZYME CORPORATION | $5,682.90 | 07/02/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152690 |
| Principal investigator 1 | Genentech, Inc. | $9,135.00 | 07/02/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655158 |
| Principal investigator 1 | Genentech, Inc. | $136.00 | 07/02/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655296 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,778.94 | 07/02/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198005 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,635.44 | 07/02/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226198043 |
| Principal investigator 1 | Genentech, Inc. | $8,725.00 | 07/01/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655166 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,742.34 | 06/26/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197941 |
| Principal investigator 1 | TG Therapeutics, Inc. | $900.00 | 06/26/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197943 |
| Principal investigator 1 | Genentech, Inc. | $441.00 | 06/25/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654941 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,652.84 | 06/24/2025 | Non-covered Recipient Entity Hope Neurology, PLLC | A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. | No dispute reported | 06/30/2026 | 1235996845 |
| Principal investigator 1 | Genentech, Inc. | $5,890.00 | 06/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655173 |
| Principal investigator 1 | Genentech, Inc. | $5,032.00 | 06/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655292 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 06/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655078 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 06/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655082 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 06/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655085 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 06/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655089 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 06/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655093 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 06/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655099 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654528 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654550 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654569 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654595 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654603 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654665 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,680.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654671 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654675 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654684 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654688 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 06/20/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654691 |
| Principal investigator 1 | Genentech, Inc. | $1,508.00 | 06/18/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655177 |
| Principal investigator 1 | TG Therapeutics, Inc. | $600.00 | 06/18/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197939 |
| Principal investigator 1 | GENZYME CORPORATION | $3,450.00 | 06/16/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152637 |
| Principal investigator 1 | Genentech, Inc. | $133.00 | 06/16/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655281 |
| Principal investigator 1 | Genentech, Inc. | $4,050.00 | 06/12/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655149 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,423.00 | 06/12/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190300091 |
| Principal investigator 1 | Genentech, Inc. | $56.00 | 06/11/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655154 |
| Principal investigator 1 | TG Therapeutics, Inc. | $25.00 | 06/10/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197937 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,032.67 | 06/09/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197935 |
| Principal investigator 1 | Genentech, Inc. | $10,591.00 | 06/06/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654948 |
| Principal investigator 1 | Genentech, Inc. | $150.00 | 06/05/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654944 |
| Principal investigator 1 | TG Therapeutics, Inc. | $7,315.00 | 06/04/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197931 |
| Principal investigator 1 | TG Therapeutics, Inc. | $9,119.82 | 06/04/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197933 |
| Principal investigator 1 | Genentech, Inc. | $17,030.00 | 06/03/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655170 |
| Recipient | Novartis Pharmaceuticals Corporation | $1,356.78 | 06/03/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190292769 |
| Principal investigator 1 | Genentech, Inc. | $56.00 | 06/02/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655162 |
| Principal investigator 1 | TG Therapeutics, Inc. | $7,129.00 | 06/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197929 |
| Principal investigator 1 | TG Therapeutics, Inc. | $14,147.00 | 06/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197983 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,401.74 | 05/29/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197997 |
| Principal investigator 1 | Genentech, Inc. | $790.00 | 05/28/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654951 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $45.47 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654523 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654532 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $46.70 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654553 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654558 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654562 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654564 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $39.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654577 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654591 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654599 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $156.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654607 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654625 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,473.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654627 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $156.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654636 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654639 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654656 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654662 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654668 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 05/27/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654696 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 05/27/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655286 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 05/20/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655300 |
| Principal investigator 1 | GENZYME CORPORATION | $17,409.30 | 05/19/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152649 |
| Principal investigator 1 | GENZYME CORPORATION | $607.00 | 05/19/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152657 |
| Principal investigator 1 | GENZYME CORPORATION | $32.00 | 05/19/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152664 |
| Principal investigator 1 | GENZYME CORPORATION | $5,175.00 | 05/19/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152669 |
| Principal investigator 1 | Genentech, Inc. | $1,145.00 | 05/14/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655187 |
| Principal investigator 1 | Genentech, Inc. | $152,571.00 | 05/13/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655191 |
| Principal investigator 1 | Genentech, Inc. | $2,516.00 | 05/13/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655312 |
| Principal investigator 1 | TG Therapeutics, Inc. | $148.68 | 05/13/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197927 |
| Principal investigator 1 | Genentech, Inc. | $1,807.00 | 05/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654959 |
| Principal investigator 1 | Genentech, Inc. | $29,423.00 | 05/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655202 |
| Principal investigator 1 | TG Therapeutics, Inc. | $574.50 | 05/07/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197981 |
| Principal investigator 1 | GENZYME CORPORATION | $92.01 | 05/05/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152554 |
| Principal investigator 1 | GENZYME CORPORATION | $274.69 | 05/05/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152560 |
| Principal investigator 1 | GENZYME CORPORATION | $170.44 | 05/05/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152566 |
| Principal investigator 1 | GENZYME CORPORATION | $352.53 | 05/05/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152570 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,753.56 | 04/30/2025 | Non-covered Recipient Entity Hope Neurology, PLLC | A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. | No dispute reported | 06/30/2026 | 1235996847 |
| Principal investigator 1 | Genentech, Inc. | $36,894.00 | 04/29/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654966 |
| Principal investigator 1 | Genentech, Inc. | $780.00 | 04/29/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655303 |
| Principal investigator 1 | GENZYME CORPORATION | $5,339.00 | 04/28/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152544 |
| Principal investigator 1 | GENZYME CORPORATION | $1,020.00 | 04/28/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152575 |
| Principal investigator 1 | GENZYME CORPORATION | $5,600.00 | 04/28/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152584 |
| Principal investigator 1 | GENZYME CORPORATION | $1,275.00 | 04/28/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152588 |
| Principal investigator 1 | Genentech, Inc. | $2,516.00 | 04/28/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655315 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654538 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654544 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654556 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654574 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654581 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654586 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654612 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $84.84 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654616 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654632 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $84.84 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654641 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654645 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654648 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,473.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654652 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654660 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 04/25/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654680 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,059.00 | 04/23/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197925 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,730.00 | 04/23/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197979 |
| Recipient | TG Therapeutics, Inc. | $499.50 | 04/21/2025 | Covered Recipient Physician | RMS301 | No dispute reported | 06/30/2026 | 1226200848 |
| Principal investigator 1 | Genentech, Inc. | $360.00 | 04/18/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654955 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,002.90 | 04/17/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197995 |
| Principal investigator 1 | Genentech, Inc. | $92.00 | 04/16/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655206 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 04/16/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655332 |
| Principal investigator 1 | GENZYME CORPORATION | $4,300.00 | 04/14/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152541 |
| Principal investigator 1 | TG Therapeutics, Inc. | $12,155.82 | 04/10/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197923 |
| Principal investigator 1 | Celgene Corporation | $3,500.00 | 04/09/2025 | Non-covered Recipient Entity Hope Neurology, PLLC | A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOLOGICAL RESPONSE TO, AND THE SAFETY OF, THREE PARENTERALLY ADMINISTERED VACCINES IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD, NON-PEGYLATED INTERFERON-, OR NO DISEASE MODIFYING THERAPY | No dispute reported | 06/30/2026 | 1222306301 |
| Principal investigator 1 | TG Therapeutics, Inc. | $14,404.20 | 04/08/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197977 |
| Principal investigator 1 | GENZYME CORPORATION | $10,744.00 | 04/07/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152487 |
| Principal investigator 1 | Eli Lilly and Company | $3,200.00 | 04/04/2025 | Non-covered Recipient Entity SIBYL WRAY NEUROLOGY PC | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541860 COMPARED TO PLACEBO IN SLOWING THE OCCURRENCE OF NEW T1 GADOLINIUM-ENHANCING LESIONS IN ADULT PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS | No dispute reported | 06/30/2026 | 1187891700 |
| Principal investigator 1 | GENZYME CORPORATION | $500.00 | 04/02/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152515 |
| Principal investigator 1 | Genentech, Inc. | $1,008.00 | 04/02/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654968 |
| Principal investigator 1 | Genentech, Inc. | $1,092.00 | 04/02/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655183 |
| Principal investigator 1 | Genentech, Inc. | $18,018.00 | 04/02/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655308 |
| Recipient | TG Therapeutics, Inc. | $273.50 | 04/02/2025 | Covered Recipient Physician | RMS301 | No dispute reported | 06/30/2026 | 1226200842 |
| Recipient | TG Therapeutics, Inc. | $1,159.23 | 04/02/2025 | Covered Recipient Physician | RMS301 | No dispute reported | 06/30/2026 | 1226200844 |
| Recipient | TG Therapeutics, Inc. | $1,076.42 | 04/02/2025 | Covered Recipient Physician | RMS302 | No dispute reported | 06/30/2026 | 1226200846 |
| Principal investigator 1 | Amgen Inc. | $22,570.14 | 04/01/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis | No dispute reported | 06/30/2026 | 1246648169 |
| Principal investigator 1 | Genentech, Inc. | $5,600.00 | 04/01/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655320 |
| Principal investigator 1 | TG Therapeutics, Inc. | $7,929.00 | 03/31/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197907 |
| Principal investigator 1 | TG Therapeutics, Inc. | $14,180.00 | 03/31/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197965 |
| Principal investigator 1 | GENZYME CORPORATION | $64.00 | 03/24/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152481 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 03/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655028 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 03/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655032 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 03/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655035 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 03/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655051 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 03/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655056 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 03/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655065 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 03/24/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655069 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,874.00 | 03/21/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654396 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 03/21/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654430 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 03/21/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654450 |
| Principal investigator 1 | Genentech, Inc. | $3,313.00 | 03/21/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | OCARINA 3 | No dispute reported | 06/30/2026 | 1211654963 |
| Principal investigator 1 | Genentech, Inc. | $235.00 | 03/21/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655324 |
| Principal investigator 1 | Genentech, Inc. | $433.00 | 03/20/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211655195 |
| Principal investigator 1 | Genentech, Inc. | $4,284.00 | 03/20/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211655198 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,516.00 | 03/20/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197921 |
| Principal investigator 1 | TG Therapeutics, Inc. | $10,039.00 | 03/20/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197975 |
| Principal investigator 1 | GENZYME CORPORATION | $17,600.00 | 03/17/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152399 |
| Principal investigator 1 | GENZYME CORPORATION | $1,600.00 | 03/17/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152462 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654384 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654388 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $125.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654404 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654408 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654412 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654417 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654420 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $84.84 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654423 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $156.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654445 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654474 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $20.25 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654483 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654490 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 03/12/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654520 |
| Principal investigator 1 | Genentech, Inc. | $25.00 | 03/12/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211655329 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,673.60 | 03/10/2025 | Non-covered Recipient Entity Paradigm Clinical Research Centers, Inc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226149021 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,337.20 | 03/10/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197985 |
| Principal investigator 1 | TG Therapeutics, Inc. | $11,719.00 | 03/05/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197919 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,364.00 | 03/05/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197973 |
| Principal investigator 1 | GENZYME CORPORATION | $214.00 | 03/04/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152503 |
| Principal investigator 1 | Celgene Corporation | $11,508.90 | 02/28/2025 | Non-covered Recipient Entity Hope Neurology, PLLC | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) | No dispute reported | 06/30/2026 | 1222306231 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $585,023.33 | 02/28/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190300097 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,217.30 | 02/28/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197963 |
| Principal investigator 1 | TG Therapeutics, Inc. | $21,500.00 | 02/28/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198095 |
| Principal investigator 1 | TG Therapeutics, Inc. | $617.00 | 02/25/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197917 |
| Principal investigator 1 | GENZYME CORPORATION | $5,615.00 | 02/24/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152434 |
| Principal investigator 1 | GENZYME CORPORATION | $59.64 | 02/24/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152444 |
| Principal investigator 1 | GENZYME CORPORATION | $2,750.00 | 02/24/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152455 |
| Recipient | Genentech, Inc. | $13,936.00 | 02/20/2025 | Covered Recipient Physician | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211538941 |
| Principal investigator 1 | TG Therapeutics, Inc. | $29,020.00 | 02/20/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197915 |
| Principal investigator 1 | TG Therapeutics, Inc. | $7,603.50 | 02/20/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197971 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654400 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654425 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $300.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654434 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $500.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654438 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $28.71 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654442 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $31.92 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654454 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $39.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654459 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654465 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,473.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654479 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $69.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654496 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $156.00 | 02/19/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654505 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $90,497.51 | 02/19/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse | No dispute reported | 06/30/2026 | 1190304725 |
| Principal investigator 1 | GENZYME CORPORATION | $1,250.03 | 02/18/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152477 |
| Principal investigator 1 | GENZYME CORPORATION | $203.00 | 02/18/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152509 |
| Recipient | Genentech, Inc. | $2,800.00 | 02/18/2025 | Covered Recipient Physician | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211538970 |
| Recipient | Genentech, Inc. | $65.00 | 02/18/2025 | Covered Recipient Physician | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211538988 |
| Recipient | Genentech, Inc. | $14,444.00 | 02/14/2025 | Covered Recipient Physician | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211538954 |
| Recipient | Genentech, Inc. | $121.00 | 02/13/2025 | Covered Recipient Physician | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211538959 |
| Principal investigator 1 | TG Therapeutics, Inc. | $7,369.00 | 02/11/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197913 |
| Principal investigator 1 | GENZYME CORPORATION | $8,650.00 | 02/10/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152384 |
| Recipient | Genentech, Inc. | $9,051.00 | 02/07/2025 | Covered Recipient Physician | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211538966 |
| Recipient | Genentech, Inc. | $68.00 | 02/07/2025 | Covered Recipient Physician | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211538984 |
| Recipient | Genentech, Inc. | $12,822.00 | 02/05/2025 | Covered Recipient Physician | OCARINA 3 | No dispute reported | 06/30/2026 | 1211538929 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,429.00 | 02/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197911 |
| Principal investigator 1 | TG Therapeutics, Inc. | $15,610.23 | 02/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197967 |
| Principal investigator 1 | TG Therapeutics, Inc. | $10,201.88 | 02/01/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197969 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,831.23 | 01/31/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190300095 |
| Principal investigator 1 | TG Therapeutics, Inc. | $18,201.20 | 01/31/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197961 |
| Principal investigator 1 | TG Therapeutics, Inc. | $12,713.00 | 01/31/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226198093 |
| Recipient | Genentech, Inc. | $3,317.00 | 01/28/2025 | Covered Recipient Physician | OCARINA 3 | No dispute reported | 06/30/2026 | 1211538933 |
| Recipient | Genentech, Inc. | $1,139.00 | 01/28/2025 | Covered Recipient Physician | OCARINA 3 | No dispute reported | 06/30/2026 | 1211538936 |
| Recipient | Genentech, Inc. | $92.00 | 01/28/2025 | Covered Recipient Physician | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211538950 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,404.64 | 01/27/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197991 |
| Principal investigator 1 | GENZYME CORPORATION | $735.00 | 01/24/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152394 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 01/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654392 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,473.00 | 01/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654470 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,680.00 | 01/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654487 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $693.00 | 01/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654500 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,473.00 | 01/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654508 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $242.00 | 01/22/2025 | Non-covered Recipient Entity Sibyl Wray | Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE | No dispute reported | 06/30/2026 | 1211654515 |
| Recipient | Genentech, Inc. | $232.00 | 01/22/2025 | Covered Recipient Physician | Ocrelizumab RMS High Dose Study | No dispute reported | 06/30/2026 | 1211538945 |
| Recipient | Genentech, Inc. | $5,997.00 | 01/17/2025 | Covered Recipient Physician | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211538979 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $363,270.82 | 01/15/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190304721 |
| Principal investigator 1 | GENZYME CORPORATION | $2,775.00 | 01/13/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152497 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 01/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655039 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 01/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655047 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 01/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655060 |
| Principal investigator 1 | Roche Products Limited | $338.00 | 01/09/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | No dispute reported | 06/30/2026 | 1211655074 |
| Recipient | Genentech, Inc. | $133.00 | 01/08/2025 | Covered Recipient Physician | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211538962 |
| Recipient | Genentech, Inc. | $68.00 | 01/08/2025 | Covered Recipient Physician | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211538975 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $290,970.23 | 01/08/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190300093 |
| Recipient | Amgen Inc. | $32,550.90 | 01/07/2025 | Covered Recipient Physician | A Randomized, Double Blind, Parallel Group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692, and Ocrevus (Ocrelizumab) in Subjects with Relapsing Remitting Multiple Sclerosis | No dispute reported | 06/30/2026 | 1246637258 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,981.00 | 01/07/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190300087 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $140,470.45 | 01/07/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes | No dispute reported | 06/30/2026 | 1190304727 |
| Principal investigator 1 | GENZYME CORPORATION | $890.00 | 01/06/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152520 |
| Principal investigator 1 | GENZYME CORPORATION | $310.00 | 01/06/2025 | Non-covered Recipient Entity Sibyl Wray Md Neurology Pc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226152527 |
| Principal investigator 1 | TG Therapeutics, Inc. | $12,861.60 | 01/03/2025 | Non-covered Recipient Entity Hope Neurology MS Center | TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226197959 |
| Principal investigator 1 | TG Therapeutics, Inc. | $10,112.00 | 01/02/2025 | Non-covered Recipient Entity Hope Neurology MS Center | (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | No dispute reported | 06/30/2026 | 1226197909 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,383,338.02 | 01/01/2025 | Non-covered Recipient Entity SIBYL WRAY MD NEUROLOGY PC | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190304723 |